If you have been reading about certificate of analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-14. Numbers and descriptions here follow the published literature rather than marketing material.
Additional techniques address components that reversed-phase chromatography may not resolve. Ion-exchange chromatography separates by charge, size-exclusion chromatography detects aggregates, and capillary electrophoresis offers high separation efficiency. Water content is measured by Karl Fischer titration, residual solvents by gas chromatography, and elemental impurities by inductively coupled plasma mass spectrometry. Amino acid analysis or nitrogen determination can estimate peptide content on a mass basis. Purity is frequently reported as area percent, yet standardized comparison across laboratories remains an open question because methods and reporting practices differ.
Peptide purity testing measures how much of a sample consists of the intended peptide sequence compared with related substances, water, counterions, and residual solvents. No single analytical method captures all of these components at once. Reversed-phase high-performance liquid chromatography with ultraviolet detection is widely used because it separates peptides by hydrophobicity. The reported purity value therefore depends on the chosen method, column, mobile phase, and detection wavelength. Established practice treats purity as method-dependent rather than an absolute property of the material.
Chromatographic separation resolves truncated, oxidized, deamidated, and epimerized peptide variants when their retention times differ from the target. Mass spectrometry confirms molecular mass and can reveal modifications that UV detection misses. Liquid chromatography coupled to mass spectrometry combines separation with identity information, which helps distinguish a pure target from a co-eluting impurity. UV-based area percent can overestimate purity if an impurity lacks a chromophore or if the target and impurity have similar response factors. Researchers often report both chromatographic purity and mass confirmation to give a fuller picture.
Stability testing examines how purity changes under controlled conditions. Samples are stored at defined temperatures, such as -20 °C or -80 °C, and analyzed at intervals. Lyophilized powders are generally more stable than solutions because water promotes hydrolysis and aggregation. Repeated freeze-thaw cycles can also degrade peptides, especially those with oxidation-prone residues. Accelerated studies at elevated temperature provide useful comparisons, but they do not always predict long-term behavior at lower temperatures.
Handling practices influence measured purity. Peptides may adsorb to plastic or glass surfaces, particularly when hydrophobic or positively charged. Weighing hygroscopic powders can introduce water and alter concentration. Dissolving in appropriate solvents and using low-binding tubes can reduce losses. Each laboratory should validate its own procedures because recovery and stability vary with peptide sequence, formulation, and container material. Open questions remain about how best to standardize stability reporting across different peptide classes.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized peptides commonly appear as powders; color can vary with sequence. |
| Solubility class | Variable; often soluble in water or aqueous buffer | Depends on sequence, charge, and hydrophobicity. |
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light; avoid repeated freeze-thaw cycles. |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity confirmation. |
| Common synonyms | Peptide purity analysis; peptide purity assay | Used in certificate of analysis and quality control contexts. |
Reverse-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. It separates components by hydrophobicity on a column with a water-organic mobile phase. Ultraviolet absorbance at 214 nm or 220 nm detects peptide bonds. The main peak area as a percentage of total peak area gives a purity figure. This figure depends on column, gradient, wavelength, and how peaks are integrated, so it is method-specific rather than absolute.
Mass spectrometry provides complementary information by measuring molecular mass. Electrospray ionization or matrix-assisted laser desorption/ionization can confirm the expected peptide mass and reveal related impurities with different masses. It does not directly quantify all species because ionization efficiency varies. When coupled to liquid chromatography, LC-MS can assign masses to chromatographic peaks. This helps distinguish target peptide from truncation, oxidation, or deletion products. Mass accuracy and resolution determine how confidently a mass can be matched to a proposed structure.
Storage conditions influence purity and therefore testing outcomes. Lyophilized peptides are generally kept cool and dry, while solutions may require refrigeration or freezing depending on sequence and buffer. Repeated freeze-thaw cycles can promote aggregation, oxidation, or hydrolysis. Testing after storage should use the same validated method as release testing to allow comparison. Stability studies examine how purity changes over time under defined temperature and humidity conditions. Results are compared against baseline data collected at release.
Regulatory frameworks treat peptide purity as part of product quality, though requirements vary by intended use and jurisdiction. Investigational materials may need identity, strength, quality, and purity documentation. Compendial monographs, when available, specify tests and acceptance criteria for certain peptides. For research peptides, oversight is often less prescriptive, and buyers may rely on supplier documentation. Open questions remain about how to standardize impurity reporting across laboratories and how to define purity for complex or modified peptides.
Quality control for peptide products relies on written procedures, batch records, and certificates of analysis. A certificate of analysis typically lists the test methods, specifications, and results for a specific lot. Batch records document synthesis, purification, and testing steps so that results can be traced to process conditions. Method validation establishes accuracy, precision, specificity, linearity, and limits of detection. These records support consistency across lots and allow laboratories to investigate deviations when a specification is not met.
== Particle size characterization == Because micronized powders are heterogeneous in both size and shape, "particle size" is defined operationally as an equivalent spherical diameter — the diameter of a sphere that would produce the same response in a given measurement technique. Different techniques therefore yield different equivalent diameters for the same powder, and a complete specification typically reports both the measurement method and the statistical descriptors of the distribution. The dominant technique for pharmaceutical micronization is laser diffraction, standardized internationally by ISO 13320 and harmonized in the United States Pharmacopeia general chapter <429> Light Diffraction Measurement of Particle Size and equivalent texts in the European Pharmacopoeia and Japanese Pharmacopoeia. Laser diffraction measures the angular intensity pattern produced when a dilute particle dispersion is illuminated by a coherent light source, and applies either Mie or Fraunhofer optical theory to invert the pattern into a volume-weighted size distribution. The method is applicable from approximately 0.1 μm to 3 mm, covers the entire size range of pharmaceutical micronization, and is non-destructive and fast. The distribution is most commonly summarized by the volume-weighted D-statistics: D10, D50 (the volume median diameter, equal to the mass median diameter for particles of uniform density), and D90, denoting the diameters below which 10%, 50%, and 90% of the cumulative particle volume lies.
== Diseases == There are some indications that NatB might N-terminally acetylate α-synuclein, a protein involved in Parkinson's disease. α-synuclein is a potential match for NatB enzymatic activity, as the protein starts with MD. N-terminal acetylation of α-synuclein has been found to stabilize the protein and regulate the neuronal toxicity level. NatB is also found to be essential for shutoff activity of PA-X, a protein from Influenza A virus. PA-X influences the gene expression and the immune response in a host, and NatB contributes by shutting off the RNA replication of the virus, even though the mechanism behind this is not known. There are some cancer related phenotypes where NAA20 expression was upregulated in hepatocarcinoma and liver cancer. NAA20 expression was also upregulated in by triple-negative breast cancer cells (TNBC), and studies showed that NAA20 could be targeted by TNBC cells to promote cell proliferation by activating EGFR signaling via Rab5A. Knockdown of NAA20 in vivo showed a decrease in tumor growth There are recent studies involving patients having mutations in the NAA20 gene, which were discovered by genetic screening. These patient mutations were found to affect the enzymatic properties of NatB thus probably being the cause of the various symptoms affecting their lives. These mutations are rare, involving only seven individuals from three different families reported so far, but all various mutations that have been found are on the NAA20 gene.
Human serum albumin is the main protein of human blood plasma. It makes up around 50% of human plasma proteins. It binds water, cations (such as Ca2+, Na+ and K+), fatty acids, hormones, bilirubin, thyroxine (T4) and pharmaceuticals (including barbiturates). Its main function is to regulate the oncotic pressure of blood. The isoelectric point of albumin is 4.7. Alpha-fetoprotein is a fetal plasma protein that binds various cations, fatty acids and bilirubin. Vitamin D-binding protein binds to vitamin D and its metabolites, as well as to fatty acids. Afamin binds vitamin E. It seems to carry lipidated Wnt proteins and Vitamin E around. Extracellular matrix protein 1 is a less canonical albumin. It regulates bone mineralization. The four canonical human albumins are arranged on chromosome 4 region 4q13.3 in a tandem manner.
Recent research has shown that commercially available UVA LEDs (365 nm) are already effective disinfection and sterilization devices. UV-C wavelengths were obtained in laboratories using aluminium nitride (210 nm), boron nitride (215 nm) and diamond (235 nm).
Sources: en.wikipedia.org
MLTs receive training more exclusively in laboratory sciences without the basic science coursework often required by MLS programs; however, there are many MLT training programs that require substantial basic didactic science course work prior to entry into a clinical practicum. Although the didactic coursework may be less for the MLT, the clinical practicum, in many cases, is similar to that of the MLS student's. This equates to MLTs who are well equipped to enter the work force with relevant and knowledge based practical application. The shorter training time may be attractive to many students, but there are disadvantages to this route. MTs, MLSs and CLSs usually earn higher salaries and have more responsibilities than MLTs. In 2018, medical laboratory technicians earned an average salary of $51,219, while medical laboratory scientists earned a salary of $67,888. An added disadvantage for MLTs is that some institutions will only employ MLSs, although that practice is starting to change due to recent efforts in cost reduction, and due to staffing shortages. In practice, the term medical laboratory technician may apply to persons who are trained to operate equipment and perform tests, usually under the supervision of the certified medical technologist or laboratory scientist. Depending on the state where employment is granted, the job duties between MLSs and MLTs may or may not be similar.
== Medical uses == As of 2022, across the European countries where etifoxine has been approved (including France, Luxembourg, Malta, Romania and Bulgaria), the main approved indication is for the treatment of the psychosomatic manifestations of anxiety. When etifoxine was first approved in France in 1979, the original indication was for the treatment of "psychosomatic manifestations of anxiety, for instance autonomic dystonia, particularly with cardiovascular expression". Over time, the indication for etifoxine has been more formalized as the treatment of adjustment disorder (situational depression) with anxiety (ADWA) (for example, stress-related anxiety). Etifoxine has been found to reduce scores on the Hamilton Anxiety Rating Scale (HAM‑A) in people with adjustment disorder with anxiety by approximately 50 to 75% after 4 weeks of treatment in clinical trials (as per the AMETIS, ETILOR, ETIZAL, STRETI studies). The medication is similarly effective or more effective than benzodiazepines like lorazepam, alprazolam, and clonazepam and more effective than buspirone for adjustment disorder with anxiety on the basis of directly comparative randomized controlled trials. However, in the AMETIS study, both etifoxine and lorazepam failed to show greater effectiveness over placebo. In the trials comparing etifoxine to clonazepam, lorazepam, and alprazolam, total daily doses of the benzodiazepines were limited to their maintenance daily dose, set at 1 mg clonazepam, 2 mg lorazepam, and 1.5 mg alprazolam, divided across 3 doses per day.
Gluten exorphins are a group of opioid peptides formed during the digestion of the gluten protein. These peptides work as external regulators for gastrointestinal movement and hormonal release. The breakdown of gliadin, a polymer of wheat proteins, creates amino acids that stop the gluten epitopes from entering the immune system to activate inflammatory reactions. During this process, gluten does not fully break down, thus increasing the presence of gluten exorphins. Because of this, researchers think this is what might lead to various diseases. Research shows the benefits of gluten- and casein-free diets for people with diseases and disorders connected to gluten exorphins. The mechanism behind this is still unknown. There is a possibility that gluten has deleterious effects on the human digestive system. When people are more susceptible to gluten and casein allergies, the weakened intestinal lining allows gluten exorphin to flow.
Sources: en.wikipedia.org
It usually refers to the relative peak area of the target peptide in a chromatogram, not the mass fraction of the entire sample. Different analytical methods can yield different purity values. Water, counterions, and residual solvents are excluded unless the calculation specifies otherwise.
A single method can miss co-eluting impurities, salts, water, or structural modifications. Orthogonal techniques separate compounds by different properties, such as hydrophobicity, charge, or size. Combining results gives a more complete assessment of sample composition.
No, purity measures the amount of target relative to other peaks, not the identity or sequence of the target. Mass spectrometry and sequencing may be needed to confirm structure. A high-purity sample can still contain a peptide with an incorrect sequence.
It typically includes the peptide sequence, molecular mass, purity method and result, storage recommendations, and date of analysis. Raw chromatograms and mass spectra may be provided on request. The absence of method details makes a purity value difficult to interpret.